Promega's Política de cookies

Empleamos cookies y tecnologías similares para mantener la funcionalidad de nuestro sitio web, analizar su rendimiento, mejorar el funcionamiento y mostrar contenido personalizado. Algunas cookies son esenciales para el buen funcionamiento de nuestro sitio web. El resto no serán instaladas en su equipo sin su consentimiento. Visite la Política de Cookies para obtener mayor detalle.

NanoBRET® TE Intracellular RAS Assay Technical Manual

Instructions for Use of Product(s)
N8010, N8012, N8013

Literature # TM717

NanoBRET® Target Engagement (TE) Assays measure compound binding to select target proteins within intact cells and have been applied successfully to study multiple target classes. NanoBRET® TE Assays quantify target engagement using bioluminescence resonance energy transfer (BRET), which is the transfer of energy between a luminescent donor and fluorescent acceptor that only occurs when the donor and acceptor are in close proximity.

The NanoBRET® TE Intracellular RAS Assay measures compound binding  to a selected RAS target protein in the presence of cellular factors that affect target engagement potency. Specifically, the assay can quantify apparent intracellular affinity of a test compound for full-length multimeric RAS proteins inside living cells and can be used to study many RAS variants, such as KRAS, HRAS and related mutants.

Whereas the original NanoBRET® target engagement assays used intact NanoLuc® luciferase fused to a target protein as the energy donor, the NanoBRET® TE Intracellular RAS Assay uses the NanoLuc® Binary Technology (NanoBiT®), a structural complementation system comprised of a large luciferase subunit (LgBiT) and a small complementary peptide (SmBiT(q)).

Summary of Changes:
The following changes were made to the 4/24 revision of this document:
1. In Section 4, the definition of BRETMax control was revised.
2. In Section 4.D, additional details were added to Step 2, and Step 3 and 3.C were revised.
3. NanoBRET was updated to a registered trademark.

 

Revised 4/24.